Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

About Florida Cancer Specialists & Research Institute, LLC: (Homepage)

Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

Connect with us:

Latest from Florida Cancer Specialists & Research Institute


Florida Cancer Specialists & Research Institute Participates in Global Gathering to Share Advances in Oncology Pharmacy Services

June 24, 2022

Florida Cancer Specialists & Research Institute clinicians and leaders shared the latest advances in oncology pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association 2022 Spring Forum held last month in Atlanta.

Florida Cancer Specialists & Research Institute Expands Care With New Cancer Center Location in Lee County

June 21, 2022

Florida Cancer Specialists & Research Institute, LLC has opened a new state-of-the-art facility at 8981 Colonial Center Drive in Fort Myers to provide comprehensive treatments and a variety of services to adults with cancer and other diseases.

Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer

June 07, 2022

Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.

Florida Cancer Specialists & Research Institute Physicians Serve as Panelists for FLASCO Training Program

April 25, 2022

Two medical oncologists from Florida Cancer Specialists & Research Institute participated in the Florida Society of Clinical Oncology Fellow & Resident Educational Training Program. The program featured respected keynote speakers to share helpful information for transitioning into the oncology workforce.

Margarett Ellison, MD, Named National Gynecologic Oncology Observation Site

March 31, 2022

Margarett Ellison, MD, gynecologic oncologist with Gynecologic Oncology of Tallahassee, A Division of Florida Cancer Specialists & Research Institute, has been designated as a National GYN Oncology Observation Site for Intuitive Surgical.

x